基本信息
views: 127
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. H. Eric Xu obtained his bachelor and master degrees in 1985 and 1988, both from Tsinghua University in Beijing, China. He then went to Duke University and the University of Texas Southwestern Medical Center, where he earned his Ph.D. in molecular biology and biochemistry in 1994. Following a postdoctoral fellowship with Dr. Carl Pabo at MIT, he moved to GlaxoWellcome in 1996 as Research Investigator I. He was promoted to Investigator II in 1999 and again to Senior Investigator in 2001. Dr. Xu joined Van Andel Research Institute (VARI) as a Senior Scientific Investigator in 2002, became a Distinguished Investigator/Professor in 2007, and served as the Director of the Center for Structural Biology and Drug Discovery and an executive committee member of VARI in 2010. In July 2010, Dr. Xu established and served as the distinguished Director of the VARI-SIMM Center for Drug Discovery at Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences. He also serves as the founding Director of the Key Laboratory of Receptor Research of Chinese Academy of Sciences. Research in his group cover structures and drug discovery of nuclear hormone receptors, G-protein coupled receptors, and plant hormones. He has published over 240 papers, with over 29,000 citations. Two of his research papers on plant hormone signaling were selected as top 10 breakthroughs by Science in 2009 and by Chinese Academy of Sciences in 2014. His X-ray laser structure of the first GPCR-arrestin complex was also selected as a top 10 breakthrough by Chinese Academy of Sciences in 2016 and was recognized by the 2016 Hans Neurath Award of Protein Society and the 2016 Wuxi outstanding achievement award. Since September 2019, Dr. Xu returned to SIMM as a Full-Time Professor and a Shanghai Talent-Summit Endowed Professor at SIMM. His research at SIMM has produced three small molecule drugs that have entered clinical trials, including VV116, a nucleoside analog that has been approved for treating COVID-19 after an outstanding efficacy from a Phase 3 clinical trial in Uzbekistan. Dr. Xu was awarded with Tan Jiazhen Life Science Career Achievement Award in 2021 and the Wu Jieping - Paul Janssen Medical & Pharmaceutical Award in 2022.
Research Interests
Papers共 417 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Zhangcheng Chen,Jing Yu,Huan Wang,Peiyu Xu,Luyu Fan, Fengxiu Sun,Sijie Huang,Pei Zhang, He Huang,Shuo Gu, Bowen Zhang,Yue Zhou,
Cellno. 9 (2024): 2194-2208.e22
Nature Communicationsno. 1 (2024): 1-10
CELL DISCOVERYno. 1 (2024): 48-48
Cell research (2024)
chinaxiv(2024)
Cited0Views0Bibtex
0
0
Nature Reviews Endocrinologyno. 6 (2024): 1-17
Heng Zhang,Yu-Ling Yin,Antao Dai, Tianwei Zhang,Chao Zhang,Canrong Wu,Wen Hu,Xinheng He, Benxun Pan,Sanshan Jin,Qingning Yuan,Ming-Wei Wang,
Natureno. 8015 (2024): 247-254
Sanshan Jin,Shimeng Guo,Youwei Xu,Xin Li,Canrong Wu,Xinheng He, Benxun Pan, Wenwen Xin, Heng Zhang,Wen Hu,Yuling Yin, Tianwei Zhang,
Cell discoveryno. 1 (2024): 58-58
Cell researchpp.1-4, (2024)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn